FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease

2 years ago

CAMBRIDGE, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving…

StateHouse and Pelorus Capital Group Enter into Strategic Arrangement to Operate Humboldt County Cultivation Facility

2 years ago

StateHouse to Provide Project Management, Operational Oversight and Strategic Direction at Humboldt County Cultivation FacilitySAN DIEGO and TORONTO, Aug. 22,…

Indegene launches Invisage, an AI-enabled hybrid omnichannel sales and marketing platform to improve HCP impact for life sciences companies

2 years ago

Invisage logo Invisage logoPRINCETON, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company today announced…

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

2 years ago

Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate…

Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President, People & Culture

2 years ago

Julia Macharey Photograph of Julia Macharey standing up and looking into the camera.ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS22…

European Commission Approves TALVEY®▼ (talquetamab), Janssen’s Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

2 years ago

Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses,…

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

2 years ago

TORONTO, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R),…

Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease

2 years ago

ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the…

Amplifon Australia Opens Its Headquarters in Central Melbourne

2 years ago

New office building entrance Amplifon Australia Opens Its Headquarters in Central MelbourneMELBOURNE, Australia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Amplifon,…

Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

2 years ago

By coupling the chromatography method FcRn-HPLC to a pH monitor, an optimized FcRn-pH-HPLC methodology was developed allowing correlation of antibodies’…